Ossiam Cuts Stock Position in Stryker Co. (NYSE:SYK)

Ossiam lowered its holdings in Stryker Co. (NYSE:SYK - Free Report) by 13.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 8,606 shares of the medical technology company's stock after selling 1,281 shares during the period. Ossiam's holdings in Stryker were worth $3,099,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the business. Chicago Capital LLC raised its holdings in shares of Stryker by 3.1% in the 4th quarter. Chicago Capital LLC now owns 195,052 shares of the medical technology company's stock worth $70,228,000 after purchasing an additional 5,841 shares during the period. Zhang Financial LLC increased its position in Stryker by 55.0% in the fourth quarter. Zhang Financial LLC now owns 114,889 shares of the medical technology company's stock worth $41,366,000 after buying an additional 40,784 shares during the last quarter. Appleton Partners Inc. MA raised its stake in shares of Stryker by 5.0% in the fourth quarter. Appleton Partners Inc. MA now owns 29,222 shares of the medical technology company's stock valued at $10,521,000 after buying an additional 1,400 shares during the period. Metis Global Partners LLC increased its holdings in Stryker by 10.2% in the 4th quarter. Metis Global Partners LLC now owns 16,841 shares of the medical technology company's stock worth $6,064,000 after acquiring an additional 1,561 shares during the last quarter. Finally, US Bancorp DE increased its holdings in Stryker by 0.5% in the 4th quarter. US Bancorp DE now owns 182,825 shares of the medical technology company's stock worth $65,829,000 after acquiring an additional 976 shares during the last quarter. Institutional investors own 77.09% of the company's stock.

Stryker Trading Up 1.1 %

NYSE:SYK traded up $3.83 during trading hours on Thursday, reaching $360.94. The company's stock had a trading volume of 1,349,722 shares, compared to its average volume of 1,357,112. The firm has a 50-day simple moving average of $368.69 and a 200-day simple moving average of $372.95. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95. Stryker Co. has a 1 year low of $314.93 and a 1 year high of $406.19. The firm has a market capitalization of $137.77 billion, a price-to-earnings ratio of 46.51, a PEG ratio of 2.93 and a beta of 0.93.

Stryker (NYSE:SYK - Get Free Report) last issued its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter in the previous year, the firm posted $3.46 earnings per share. Research analysts expect that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be given a dividend of $0.84 per share. The ex-dividend date is Monday, March 31st. This represents a $3.36 annualized dividend and a yield of 0.93%. Stryker's payout ratio is currently 43.30%.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on SYK. BTIG Research set a $403.00 target price on shares of Stryker and gave the stock a "buy" rating in a research note on Monday, April 14th. Needham & Company LLC reiterated a "buy" rating and issued a $442.00 price objective on shares of Stryker in a research note on Friday, March 21st. JMP Securities restated a "market perform" rating on shares of Stryker in a research report on Tuesday, February 18th. JPMorgan Chase & Co. raised their price target on Stryker from $420.00 to $445.00 and gave the stock an "overweight" rating in a report on Wednesday, January 29th. Finally, Argus set a $450.00 price objective on Stryker in a report on Monday, February 3rd. Five investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $423.53.

Insider Buying and Selling at Stryker

In other news, Director Ronda E. Stryker sold 201,392 shares of Stryker stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the sale, the director now owns 3,642,075 shares of the company's stock, valued at approximately $1,428,567,498. The trade was a 5.24 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Allan C. Golston sold 2,458 shares of the firm's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the completion of the sale, the director now owns 14,895 shares of the company's stock, valued at $5,705,827.65. This trade represents a 14.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 5.20% of the company's stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.